Following our series of posts in biosimilars and immunogenicity testing, a recent paper by Korea company Celltrion describes the characterisation of Remsina®, the first mAb biosimilar (for Remicade® – infliximab) approved in Europe. In this study, ELISA arrays for conformational studies were used for the Higher Order Structure characterisation and compatibility analysis.
Reprogramming-qualified B18R Recombinant Protein, Carrier-free is of interest for cellular reprogramming and other applications requiring RNA-mediated gene delivery. B18R protein is a Vaccinia virus-encoded receptor with specificity for mouse, human, rabbit, pig, rat and cow Type 1 interferons and has potent neutralizing capability acting as a decoy receptor for Type 1 interferons.
Biological Activity
- Stemfactor B18R Recombinant Protein, Carrier-free bioactivity is demonstrated by the neutralization of IFN-alpha or IFN-beta effects in an assay of IL-12 production from CD40L-activated monocytes.
- The biological function is validated by down-regulation of gene expression by qRT-PCR of TLR3, IFIT1, and OASI in response to B18R treatment on human fibroblasts to levels equivalent to non-transfected cells.
- The efficiency of mRNA reprogramming is tested by performing mRNA reprogramming with OKSML on neonatal foreskin fibroblasts and demonstrating greater than 0.5% iPSC colony formation.
NuFF feeder cells plated at at 2.5 x 10E5 cells per well on Day -2.
Images were captured 24 hours after plating and represent an appropriate NuFF feeder layer density for plating target cells on Day -1.
Previously only available as part of the mRNA Reprogramming Kit or microRNA Booster Kit, Reprogramming-qualified B18R Recombinant Protein, Carrier-free is now available individually.
Top contributors
